| Similar Articles |
|---|
 |
The Motley Fool
August 21, 2008
Brian Lawler |
Regeneron's Results Clearing Up The drugmaker presents new data on a compelling candidate for macular degeneration treatment.   |
The Motley Fool
November 23, 2010
Brian Orelli |
Less of a Poke in the Eye Regeneron Pharmaceuticals was up nearly 20% yesterday after the drugmaker announced the results for two phase 3 trials testing VEGF Trap-Eye in wet AMD patients. |
The Motley Fool
September 2, 2011
Brian D. Pacampara |
Regeneron Pharmaceuticals Shares Jumped: What You Need to Know Shares of drugmaker Regeneron Pharmaceuticals popped 10% in intraday trading Friday after The New York Times reported that Roche's age-related macular degeneration treatment Avastin led to vision loss in several California patients. |
The Motley Fool
February 29, 2008
Brian Lawler |
Regeneron's Orphan Charms the FDA Regeneron Pharmaceuticals receives marketing approval from the FDA for a treatment that targets a very rare inflammatory disease. |
The Motley Fool
November 19, 2011
Luke Timmerman |
Regeneron Wins FDA Approval for Macular-Degeneration Drug The company can begin selling Eylea, which treats the leading cause of blindness in the elderly. |
The Motley Fool
October 2, 2007
Brian Orelli |
Regeneron Sees Positive Phase 2 Data Regeneron Pharmaceuticals and partner Bayer HealthCare see a bright future for their age-related macular degeneration treatment after announcing positive phase 2 data. |
The Motley Fool
April 29, 2011
Cindy Johnson |
Regeneron Pharmaceuticals Shares Plunged: What You Need to Know Regeneron Pharmaceuticals dropped 12% in intraday trading today after an analyst at RBC Capital downgraded the stock from outperform to sector perform. |
The Motley Fool
June 16, 2011
Brian Orelli |
No Poke in the Eye Here What's the biggest sign that the Food and Drug Administration is all set to approve Regeneron Pharmaceuticals' Eylea? The briefing documents for the advisory committee contained a proposed version of the label. |
The Motley Fool
December 27, 2010
Brian Orelli |
Painful Clinical Hold? Not Really. Regeneron offers the benefits of a full pipeline. |
The Motley Fool
June 20, 2011
Brian Orelli |
See Drug, Approve Drug An approval of Regeneron's macular degeneration Eylea looks likely. |
The Motley Fool
August 18, 2011
Brian Orelli |
A Poke in the Eye From the FDA FDA extends its review of Regeneron Pharmaceuticals' macular degeneration drug by three months. |
The Motley Fool
July 14, 2011
Brian Orelli |
Good Data, but Lots of Competition Regeneron's sarilumab passes a phase 2b trial. |
The Motley Fool
January 10, 2012
Travis Hoium |
Regeneron Pharmaceuticals Shares Jumped: What You Need to Know Shares of Regeneron Pharmaceuticals jumped 13% today after the company said sales of Eylea were strong in the fourth quarter. |
The Motley Fool
April 27, 2011
Brian Orelli |
Falling Into the Zaltrap Lung cancer out, colon cancer in phase 3 clinical trial for Regeneron Pharmaceuticals' new drug. |
The Motley Fool
February 28, 2011
Brian Orelli |
Look Out for Big Growth From This Drug Regeneron's ultra-orphan drug Arcalyst takes a step forward toward a wider audience. |
The Motley Fool
October 14, 2011
Sean Williams |
7 FDA Decisions You Can't Afford to Ignore in Q4 These stocks are bound to move as the FDA weighs in on their prospective drugs in Q4: Bristol-Myers... BioSante... Teva... Regeneron... Transcept... Incyte... Antares Pharma... |
The Motley Fool
June 9, 2010
Brian Orelli |
The Drug Passed, but the Stock Fell? Regeneron only bats .500. |
The Motley Fool
November 21, 2011
Brian Orelli |
This Biotech Has Almost Everything Going for It Fewer injections into the eye and lower cost than the other FDA-approved drug: What's not to like about Regeneron Pharmaceuticals' Eylea, which was approved on Friday? |
The Motley Fool
November 21, 2011
David Williamson |
Market Volatility = Biotech Opportunity Gilead buys Pharmasset, Spectrum gets a break, and Eylea's approved. |
The Motley Fool
August 22, 2011
Brian Orelli |
Speedy in Seattle Seattle Genetics gets an early approval of Adcentris. |
The Motley Fool
May 19, 2010
Brian Orelli |
The Biggest-Little Biotechs in the World If you do decide to invest in these biotechs before they've secured phase 3 results make sure you know what you're getting yourself into and aren't blindly following the crowd. |
The Motley Fool
July 23, 2011 |
Regeneron Pharmaceuticals Earnings Preview Regeneron Pharmaceuticals will unveil its latest earnings on Wednesday, July 27. |
The Motley Fool
September 14, 2009
Brian Orelli |
More Tests for Drug for Cancer Patients The Vanilla trial might not have come up positive, but at least sanofi-aventis and Regeneron Pharmaceuticals will keep trying to show that aflibercept is capable of helping cancer patients live longer. |
The Motley Fool
January 3, 2005
Rich Duprey |
Eying Profits in Eye Sight Macular degeneration is proving to be a field with eye-popping potential. Manufactured by Pfizer and Eyetech, a tiny biotech that went public early last year, Macugen was recently approved by the FDA. |
The Motley Fool
January 11, 2012
Brian Orelli |
A Year's Worth of Sales in 1 Month Regeneron's Eylea hits the gates running. |
The Motley Fool
November 11, 2009
Brian Orelli |
Now That's What I Call a Drug Deal Investors are regenerating their interest in Regeneron Pharmaceuticals after it extended its drug-discovery pact with sanofi-aventis. |
The Motley Fool
August 22, 2005
Rich Duprey |
Fuzzy Outlook for OSI-Eyetech Merger OSI Pharmaceuticals appears to have little to gain from its purchase of Eyetech. The situation does offer an eye-opening lesson on the risks inherent in investing in such one-trick ponies. |
The Motley Fool
July 30, 2010
Brian Orelli |
3 Development-Stage Drugmakers Worth Watching A basket of potential drugs in just one company. |
Managed Care
March 2005
Thomas Morrow |
Aptamers: Slowing Progression of AMD A single strand of nucleic acid may hold the key to treating the leading cause of severe vision loss and blindness resulting from age-related macular degeneration. |
Bio-IT World
Jul/Aug 2006 |
News Blast Health Solutions... Rna Interference... HIV Triple Combo... |
The Motley Fool
November 15, 2011
Selena Maranjian |
Make Money in Biotech and Genome Stocks the Easy Way If you expect biotech firms and companies specializing in genomics to thrive as advances in health care and medicine continue, the PowerShares Dynamic Biotech & Genome ETF could save you a lot of trouble. |
Chemistry World
April 4, 2013
Phillip Broadwith |
Regeneron expands, creating 400 new jobs US biotech Regeneron has announced that it will expand its corporate headquarters and laboratories in Tarrytown. |
The Motley Fool
January 15, 2012
Brian Orelli |
3 Lessons From the J.P. Morgan Health-Care Confab After 30 years, the conference still offers useful takeaways. This years: Some biotechs never die... In the United States, more people die from flu each year than die from HIV AIDS... Drug launches are back (maybe)... |
The Motley Fool
January 10, 2012
Brian Orelli |
Linear Growth Isn't Enough Human Genome Sciences needs to accelerate growth. |
The Motley Fool
February 12, 2009
Brian Orelli |
Cruising, but Ready to Take Off Genzyme's in wait-and-see mode. |
The Motley Fool
November 15, 2011
Selena Maranjian |
Make Money in Profitable Small Caps the Easy Way If you expect small companies to do well in coming years as the global economy recovers, the iShares S&P SmallCap 600 Index ETF could save you a lot of trouble. |
Managed Care
January 2004
Thomas Morrow |
Choking Off a Tumor's Blood Supply Angiogenesis blockade is a 30-year-old concept, but it will soon make the leap from lab bench to pharmacy shelf. |
Chemistry World
October 23, 2014
Rebecca Trager |
Amgen seeks injunction to protect patents The US biopharmaceutical company Amgen has filed a patent infringement lawsuit against Sanofi and Regeneron in the US District Court of Delaware. |
BusinessWeek
August 16, 2004
Arlene Weintraub |
The Race to Stop an Eyesight Stealer No magic bullet yet, but new drugs to fight age-related macular degeneration are near. |
